PTC Update on the Development of Ataluren in Nonsense-Mutation DMD/BMD

PTC Therapeutics says it plans to conduct additional trials of ataluren

Article Highlights:
  • Ataluren (formerly PTC124) is a stop codon read-through drug that coaxes cells to ignore nonsense mutations in the dystrophin gene and produce a functional dystrophin protein.
  • PTC Therapeutics has been developing ataluren, with initial support from MDA, for people with Duchenne or Becker muscular dystrophy due to nonsense mutations (also known as premature stop codons).
  • An earlier trial showed patients who took a lower dose of ataluren walked farther on a six-minute walk test than the high-dose or placebo groups.
  • The drug is now in extension studies for previous trial participants.
  • PTC says it is currently planning to conduct an additional, confirmatory study of low-dose ataluren compared to a placebo, whether in the context of conditional approval in Europe or to meet additional requirements in the United States.
by Margaret Wahl on July 31, 2012 - 12:37pm

New Jersey biopharmaceutical company PTC Therapeutics recently declared its intention to do whatever it takes — including an additional clinical trial — to seek approval for ataluren (formerly PTC124) as a treatment for Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) caused by nonsense mutations in the gene for the muscle protein dystrophin.

Nonsense mutations — also known as premature stop codon mutations — cause cells to stop synthesizing a protein from genetic instructions before the process is complete, resulting in production of a short, nonfunctional protein.

These mutations are believed to be the underlying cause of DMD or BMD in about 10 to 15 percent of people with these dystrophies, both of which result from a lack of dystrophin in muscle cells.

Ataluren is designed to coax cells to ignore, or "read through," nonsense mutations and synthesize a functional dystrophin protein. The drug is sometimes referred to as a "stop codon read-through" compound.

MDA Venture Philanthropy, the drug development arm of MDA's translational research program, awarded $1.5 million to PTC in 2005 for ataluren research.

PTC planning another trial to meet regulatory requirements 

In a July 11, 2012, email communication to advocacy groups, PTC said that the U.S. Food and Drug Administration (FDA) will almost certainly require an additional clinical trial of ataluren in nonsense-mutation DMD/BMD comparing low-dose ataluren to a placebo.

A 48-week, 174-participant trial suggested a benefit for those on a lower dose of ataluren with respect to the distance walked in six minutes for participants with nonsense-mutation DMD/BMD while participants on high-dose ataluren or placebo showed no benefit. (Those on the low dose walked about 100 feet farther in six minutes than those in the high-dose or placebo groups, although all groups' walking distance declined during the trial.)

In the same July communication, PTC said that it is in discussions with the European Medicines Agency (EMA) concerning the path forward in Europe, particularly the potential to file for "conditional" approval of ataluren for DMD/BMD.

"Whether in the context of conditional approval in Europe, or to meet additional requirements in the US, PTC is currently planning to conduct an additional confirmatory study of low-dose ataluren versus placebo," the communication said.

Studies remain open for participants in earlier trials

Open-label trials of ataluren for those who have previously participated in placebo-controlled trials of the drug are currently being conducted in the United States and in several other countries.

Open-label studies are those in which all participants receive the experimental treatment. Placebo-controlled studies are those in which some participants receive a placebo (look-alike, inactive drug) and in which neither the investigators nor the participants know who is receiving which treatment until the study is complete.

To learn more, also see the following:

Your rating: None Average: 4 (8 votes)
MDA cannot respond to questions asked in the comments field. For help with questions, contact your local MDA office or clinic or email publications@mdausa.org. See comment policy